PMID: 22333382Feb 16, 2012Paper

Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity

Internal Medicine
Kei KunimasaTadashi Ishida

Abstract

Gefitinib and erlotinib are first-generation small molecular inhibitors of EGFR tyrosine kinase activity. To the best of our knowledge, to date, two reports have stated that patients with NSCLC who develop severe hepatotoxicity secondary to gefitinib treatment can be safely switched to erlotinib. However, the reverse situation has not been reported. Here, we present the first case with non-small cell lung cancer harboring EGFR mutation who developed grade 3/4 hepatotoxicity after initiation of erlotinib, which resolved when therapy was changed to gefitinib. As far as we know, this is the first report showing the efficacy of gefitinib for a non-small cell lung cancer patient who developed severe hepatotoxicity while under erlotinib therapy.

References

Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey J Langer, Minesh P Mehta
Dec 31, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jie LingChandra Prakash
Feb 17, 2006·The New England Journal of Medicine·Victor J Navarro, John R Senior
Mar 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deepak KhuntiaMinesh P Mehta
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing LiSharyn D Baker
Jul 13, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Weitian LiuRobert D Odze
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group
Aug 21, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tatsuya KatayamaTetsuya Mitsudomi
Sep 11, 2009·British Journal of Clinical Pharmacology·Yi-Sheng HuangYi-Long Wu
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masayuki TakedaKazuhiko Nakagawa
May 19, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yosuke TogashiMichiaki Mishima
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Sep 8, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Geoffrey Y KuGilberto de Lima Lopes

❮ Previous
Next ❯

Citations

Apr 27, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R ShahDevron R Shah
Nov 18, 2014·Expert Opinion on Drug Metabolism & Toxicology·Yi Ling TeoAlexandre Chan
Sep 2, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Eri SugiyamaKoichi Goto
Jul 9, 2013·Critical Care Clinics·Wendy I Sligl, Thomas J Marrie
May 27, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R Shah, Joel Morganroth
Jul 1, 2015·Archives of Pathology & Laboratory Medicine·Kurt FisherRomil Saxena
May 18, 2016·Expert Opinion on Drug Metabolism & Toxicology·Kirsty Wai-Chung Lee, Stephen Lam Chan
Dec 7, 2018·Asia-Pacific Journal of Clinical Oncology·Yoshihiko SakataKazuya Ichikado
Nov 9, 2020·Critical Reviews in Oncology/hematology·Camille HouronCosmin Sebastian Voican
Aug 3, 2021·Biological & Pharmaceutical Bulletin·Iqbal Julian, Takuya Iwamoto

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.